Torben Straight Nissen took over the reins of Repertoire Immune Medicines at the tail end of 2022, at a time when the Cambridge company was in need of a reset. Nissen's arrival coincided with Repertoire’s decision to scrap its two lead drugs and lay off 65 people when Phase 1 trials against melanoma and tumors involving HPV-16 didn’t pan out.
But during that difficult period in the industry, when many biotechs that encountered challenges were forced to shut down rather than pivot, Repertoire appears to have found a new way forward.
On Monday, Repertoire announced a multi-year collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases. Repertoire will receive a $65 million upfront payment, and up to $1.8 billion for hitting development, regulatory and commercial milestones, in addition to tiered royalties.
More on this story from Boston Business Journal
Get New England news, weather forecasts and entertainment stories to your inbox. Sign up for NECN newsletters.
